CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia

This study (called CARPALL) is testing a new type of immune cell therapy — called CAR T-cell therapy — where a patient's own immune cells are engineered in a lab to recognize and destroy leukemia cells, specifically for children and young adults with a hard-to-treat blood cancer called acute lymphoblastic leukemia (ALL) whose cancer cells carry specific markers (CD19 and CD22). **You may be eligible if...** - You are 24 years old or younger - You have CD19- and CD22-positive ALL that has not responded to treatment, has relapsed (come back), or is considered too high-risk for standard treatments - Your overall health and organ function are above the minimum thresholds **You may NOT be eligible if...** - You have active hepatitis B, C, or HIV - Your oxygen levels, liver function, or kidney function are significantly abnormal - You are pregnant or breastfeeding - You have a pre-existing significant brain or nervous system condition (other than leukemia involvement) - Your leukemia cells do not carry the CD19 or CD22 markers - You have a severe active infection or require supplemental oxygen at the time of the planned cell infusion - You have severe graft-versus-host disease from a previous bone marrow transplant Talk to your doctor to see if this trial is right for you.